Peptide data sheet
Survodutide
GLP-1 · BI 456906
Verdict
promisinginvestigational; no approved human use
Quick answer
Survodutide (BI 456906) is an investigational dual agonist that activates both the GLP-1 and glucagon receptors. It is commonly researched for weight management and for metabolic dysfunction-associated steatohepatitis (MASH). Mid-stage trials reported meaningful weight and liver-marker changes, which is why the verdict is Promising rather than Proven — it is still in clinical development, is not FDA-approved, and is not available for human use.
At a glance
- Class
- GLP-1/glucagon dual receptor agonist (investigational)
- Half-life
- Supports once-weekly dosing in trials (exact human value not publicly established)
- FDA status
- Not FDA-approved; investigational, in clinical trials
Which form actually works?
Injectable (subcutaneous, once-weekly in trials)
Promising
The route used across the reported clinical trials. Weight and liver-marker results were reported here, but the compound remains investigational and is not approved for human use.
Read the full Survodutide verdictThe deep-dive: every study and Pep's honest take.Reconstitution calculatorConcentration and draw-volume math — informational only.